• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[呼吸急症的医学治疗]

[Medical treatment of respiratory emergencies].

作者信息

Battistini A

机构信息

Centro di Fisiopatologia Respiratoria Infantile, Università di Parma, Italia.

出版信息

Pediatr Med Chir. 2000 Jul-Aug;21(4):171-9.

PMID:10767976
Abstract

Of the four treatments that can be used to treat respiratory insufficiency due to laryngitis, two, nebulized adrenaline and O2 therapy, are undoubtedly effective. The inhalation of water vapour appears to be increasingly useless and may be also harmful. The use of steroids is still under debate. In recent literature, however, the utility of steroids seems to be confirmed, especially if administered per Os, and even at a relatively low single oral dose (1-2 mg/kg of prednisone). According to the official organs (see Red Book) and according to the Evidence Based Medicine (see Cochrane Library) the treatment of bronchiolitis should be limited to an eventual support therapy, i.e. O2 therapy and rehydration. However, the approach adopted by North American Hospitals and European specialists in infectious diseases is in contrast and consists in the use of beta 2 agonists and steroids in 90-100% and 40-80% of patients, respectively. This contrast could be due to a deficiency in the researches of the Evidenced Based Medicine which is obliged to retrieve studies done over 10-15 years in order to obtain a sufficient number of data for a statistically valid investigation. These studies unfortunately are not updated with regard to the dose of individual drugs and the immediate association of drugs. In particular, with regard to nebulized beta 2 agonists, the absence of a positive effect could be due to an excessively low dose in relation to the age of the patient. According to the most recent knowledge, in fact, reduced doses are no longer required for babies in consideration of age and weight. In reality an equal and even higher dose than that used in adults would be best. The other reason for a lack of response could be the absence of the association of a steroid with a beta 2 agonists at the right moment. The lack of timing in associating these two drugs could also account for the absent response to the steroid. On the basis of these considerations it would be a mistake to give up the use of beta 2 agonists and steroids. Considering also the severity and frequency of a disease as bronchiolitis. To follow the "fashion" of the Evidence Based Medicine. Recently, magnesium sulphate, ketamine and the association elium-O2 have been suggested as marginal and not revolutionary medical interventions for the treatment of asthma. Among bronchodilators, the subordinate role of anticholinergics (for ex. ipratropium bromide), and of adrenaline has been defined with respect to beta 2 agonists, in particular salbutamol. The optimisation of the administration by nebulizers of the latter has been fundamental as it has a key role in the treatment of acute severe asthma. In detail, traditional nebulizers tend to be substituted by Metered Dose Inhaler + spacer with a ratio in the dose of 5/1. The venous route is used only in very severe cases and is used late and in intensive care although a single initial intravenous administration could determine a more rapid reduction of bronchoconstriction and reduce the number of nebulized bronchodilatators that can become extremely frequent in most severe cases. For steroids, instead, the only safe therapeutic route is by PO, i.v., i.m.: nebulized steroids although used with a definitely higher dose than that used for chronic asthma, can be used only in the milder forms.

摘要

在可用于治疗喉炎所致呼吸功能不全的四种治疗方法中,有两种,即雾化肾上腺素和氧气疗法,无疑是有效的。吸入水蒸气似乎越来越无用,甚至可能有害。类固醇的使用仍存在争议。然而,在最近的文献中,类固醇的效用似乎得到了证实,尤其是口服给药时,甚至单剂量相对较低(泼尼松1 - 2毫克/千克)时。根据官方机构(见《红宝书》)以及循证医学(见《考科蓝图书馆》),毛细支气管炎的治疗应限于必要的支持性治疗,即氧气疗法和补液。然而,北美医院和欧洲传染病专家所采用的方法却与之相反,分别有90% - 100%的患者使用β2激动剂,40% - 80%的患者使用类固醇。这种差异可能是由于循证医学研究存在缺陷,为了获得足够数量的数据进行具有统计学意义的调查,它不得不检索10 - 15年前进行的研究。不幸的是,这些研究在个别药物剂量和药物的即时联合使用方面并未更新。特别是对于雾化β2激动剂,没有产生积极效果可能是因为相对于患者年龄剂量过低。事实上,根据最新知识,考虑到年龄和体重,婴儿不再需要减少剂量。实际上,给予与成人相同甚至更高的剂量可能是最佳选择。缺乏反应的另一个原因可能是没有在合适的时间将类固醇与β2激动剂联合使用。这两种药物联合使用的时机不当也可能导致对类固醇没有反应。基于这些考虑,放弃使用β2激动剂和类固醇将是一个错误。考虑到毛细支气管炎这种疾病的严重性和发病率。遵循循证医学的“潮流”。最近,硫酸镁、氯胺酮以及氦氧混合气被认为是治疗哮喘的边缘且并非革命性的医学干预措施。在支气管扩张剂中,已明确抗胆碱能药物(如异丙托溴铵)和肾上腺素相对于β2激动剂,特别是沙丁胺醇的次要作用。优化后者通过雾化器给药至关重要,因为它在急性重度哮喘的治疗中起关键作用。具体而言,传统雾化器往往被定量吸入器 + 储物罐所取代,剂量比为5/1。静脉途径仅在非常严重的情况下使用,且使用较晚且在重症监护中使用,尽管单次初始静脉给药可更迅速地减轻支气管收缩,并减少在大多数严重情况下可能极为频繁使用的雾化支气管扩张剂的次数。对于类固醇,相反,唯一安全的治疗途径是口服、静脉注射、肌肉注射:雾化类固醇尽管使用剂量肯定高于慢性哮喘,但仅可用于较轻的病例。

相似文献

1
[Medical treatment of respiratory emergencies].[呼吸急症的医学治疗]
Pediatr Med Chir. 2000 Jul-Aug;21(4):171-9.
2
[Round Table: Severe asthma in pediatrics: treatment of acute crises].[圆桌会议:儿科重症哮喘:急性发作的治疗]
Allergol Immunopathol (Madr). 1999 Mar-Apr;27(2):53-62.
3
[The origin of informed consent].[知情同意的起源]
Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27.
4
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).阿片类药物与老年人慢性重度疼痛的管理:一个国际专家小组的共识声明,重点关注世界卫生组织第三阶梯临床最常用的六种阿片类药物(丁丙诺啡、芬太尼、氢吗啡酮、美沙酮、吗啡、羟考酮)。
Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.
5
Acute asthma in emergency room.急诊室中的急性哮喘
Indian J Pediatr. 2003 Mar;70 Suppl 1:S28-33.
6
Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma.对于患有急性重度哮喘的成年人,在使用带有储雾罐的定量吸入器吸入沙丁胺醇时添加多剂量奥昔托溴铵的疗效。
J Allergy Clin Immunol. 2000 Sep;106(3):472-8. doi: 10.1067/mai.2000.108910.
7
Evidence-based treatments for acute asthma.急性哮喘的循证治疗
Respir Care. 2001 Dec;46(12):1380-90; discussion 1390-1.
8
[Treatment of acute asthma attack in the emergency department].[急诊科急性哮喘发作的治疗]
Harefuah. 2003 Nov;142(11):750-3, 806.
9
Status of inhalation therapy in bronchial asthma in adults above twelve years of age in armed forces.军队中12岁以上成年人支气管哮喘的吸入疗法现状
J Assoc Physicians India. 2005 Aug;53:681-4.
10
The diagnostic and therapeutic approach to acute bronchiolitis in hospitalized children in Israel: a nationwide survey.以色列住院儿童急性细支气管炎的诊断与治疗方法:一项全国性调查。
Isr Med Assoc J. 2000 Feb;2(2):108-10.

引用本文的文献

1
Aspergillus epiglottitis in a non-immunocompromised patient.非免疫功能低下患者的会厌曲霉病
BMJ Case Rep. 2011 Feb 24;2011:bcr1120103485. doi: 10.1136/bcr.11.2010.3485.